Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Potassium Bitartrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 128Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Evofem Biosciences Announces Financial Results for the First Quarter of 2023
    Evofem Biosciences Announces Financial Results for the First Quarter of 2023

    16 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/evofem-biosciences-announces-financial-results-for-the-first-quarter-of-2023-301853384.html

    PR NEWSWIRE
    16 Jun 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Lactic Acid, Citric Acid and Potassium Bitartrate
    FDA Confirms Paragraph IV Patent Litigation for Lactic Acid, Citric Acid and Potassium Bitartrate

    25 Apr 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-lactic-acid-citric-acid-and-potassium-bitartrate-85917.pdf

    FDA
    25 Apr 2023
    Share Share
    Evofem Biosciences receives US patent covering Phexxi composition of matter
    Evofem Biosciences receives US patent covering Phexxi composition of matter

    26 Sep 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=153448&sid=2

    PHARMABIZ
    26 Sep 2022
    Share Share
    Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide
    Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide

    16 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/large-commercial-payer-adds-phexxi-to-formulary-for-standard-plans-nationwide-301626008.html

    PRNEWSWIRE
    16 Sep 2022
    Share Share
    Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®
    Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®

    10 May 2022

    // PRESS RELEASE

    https://evofem.investorroom.com/2022-05-10-Evofem-Biosciences-to-Decrease-Cost-of-Goods-45-Percent-Through-New-Partnership-with-Bora-Pharmaceutical-Services-for-the-Commercial-Manufacturing-of-Phexxi-R

    PRESS RELEASE
    10 May 2022
    Share Share
    Evofem’s Phase III trial reveals fewer UTIs in women using Phexxi
    Evofem’s Phase III trial reveals fewer UTIs in women using Phexxi

    09 May 2022

    // PHARMAFILE

    http://www.pharmafile.com/news/635113/evofem-s-phase-iii-trial-reveals-fewer-utis-women-using-phexxi

    PHARMAFILE
    09 May 2022
    Share Share